Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian CancerSusan J. Ramus, Simon A. Gayther, Honglin Song et al.|JNCI Journal of the National Cancer Institute|2015Cited by 441
Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association ConsortiumCatherine M. Olsen, Aleksandra Gentry‐Maharaj, Mary Anne Rossing et al.|Endocrine Related Cancer|2013Cited by 230
#159 ICON8B: GCIG phase III randomised trial comparing weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy+ bevacizumab in first-line high-risk stage III-IV epithelial ovarian cancer treatment: primary progression-free survival analysisAndrew R. Clamp, Jonathan A. Ledermann, Iain A. McNeish et al.|International Journal of Gynecological Cancer|2023Cited by 4